直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

European IP Blog

EPO Enlarged Board of Appeal Finds the Cure For Poisonous Divisionals

2 December 2016

Authored and Edited by Leythem A. Wall; Adriana L. Burgy

At the end of 2012, a European Patent Office (EPO) Board of Appeal decision sent shockwaves through Europe; it concluded that a European divisional patent publication could be novelty destroying to the European parent patent from which it is derived, the so called “poisonous divisional.”

The reasoning behind the “poisonous divisional” is that the parent claims are not entitled to priority, whereas the anticipatory subject matter in the divisional publication is entitled to priority. In fact, the problem works both ways, i.e., the publication of the parent could also be novelty destroying against a divisional application whose claims are not entitled to priority.

Some EPO Board of Appeal decisions avoided this problem by treating claims as having two conceptual parts. One part is entitled to priority, hence the European divisional or parent cannot be novelty destroying.  The second part is not entitled to priority, but the same disclosures appearing in the European divisional or parent are also not entitled to priority.  Therefore, the parent or divisional application cannot anticipate the other.  Other decisions did not.

Due to the divergent EPO Board of Appeal case law on the “poisonous” issue, five questions were referred to the Enlarged Board of Appeal (EBA), EBA referral G1/15. The first question addressed whether entitlement to such partial priority could be refused for a claim with a generic expression which encompasses alternatives, but which does not explicitly separate the alternatives in the claim.

The EBA has this week issued an order of the decision for this referral addressing the first question.  The order can be found here and states:

Under the EPC, entitlement to partial priority may not be refused for a claim encompassing alternative subject-matter by virtue of one or more generic expressions or otherwise (generic "OR"-claim) provided that said alternative subject-matter has been disclosed for the first time, directly, or at least implicitly, unambiguously and in an enabling manner in the priority document. No other substantive conditions or limitations apply in this respect.

The detailed reasons for this order are forthcoming.  While we wait for those, by answering “no” to the first of the G1/15 questions, the remaining questions do not need to be addressed, and it looks like this issue of “poisonous” family members will be short-lived and can be finally put to rest.

Further background and information on G1/15, “poisonous divisional,” and the “remedy” of partial priorities can be found here.

 

Contacts

Adriana L. Burgy
Partner
Washington, DC
+1 202 408 4345
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information. 

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP